Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News
EchoIQ von 3 Analysehäusern als "Best-in-Class" bewertet - Kurszielpotenzial von über 200?%
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
669 Leser
Artikel bewerten:
(0)

QY Research Inc.: QY Research Predicts - Global Pleural Effusion Treatment Market to Touch Slightly Over US$ 6.5 Bn by 2026 End

LOS ANGELES - CA / ACCESSWIRE / February 17, 2020 / A new report titled, "Global Pleural Effusion Treatment Market Size, Status and Forecast 2020-2026" has been published by QY Research. As per the report, in 2019, the market size for Pleural Effusion Treatment was US$ 4.0 Bn and it is expected to reach slightly above US$ 6.5 Bn by the end of 2026. The market is forecasted to exhibit a healthy CAGR of 6.6% during the projected period, 2020-2026.

Awareness Regarding Pleural Effusion Treatment to Bode Well for the Market

Increasing awareness regarding the availability of Pleural Effusion Treatment and favorable government support are some of the primary reasons behind healthy growth of the global Pleural Effusion Treatment market. Extensive research and development have led to novel drug discoveries for the treatment of Pleural Effusion, thus positively impacting the growth of the market. Technological developments pertaining to Pleural Effusion Treatment may offer a boost to the market growth in future. Nevertheless, unavailability of effective treatment for Pleural Effusion may act as a challenge for the market.

Serial Thoracentesis to Gain Traction as a Key Treatment Type

The Pleural Effusion Treatment market is segregated based on the treatment type as serial thoracentesis, tube thoracostomy, pleurodesis, long-term pleural catheter, pleuroperitoneal shunt, decortication, chemotherapy, radiotherapy, and others. Serial thoracentesis is getting traction as a key treatment type as it is usually considered to be a safe process. The procedure is followed by a chest X-ray to ensure no complications have occurred.

Request Sample Report: https://www.qyresearch.com/sample-form/form/1517021/global-pleural-effusion-treatment-market

Congestive Heart Failure Incidences to Aid Malignant Pleural Effusions (MPE) Segment Growth

The report has also offered in-depth analysis of the disease application segments of Pleural Effusion Treatment market comprising Malignant Pleural Effusions (MPE) and Paramalignant Pleural Effusions (PMPE). Malignant Pleural Effusions (MPE) segment is likely to witness significant growth in future. This is on account of surge in the incidences of congestive heart failure, lung tumor, and blockage of blood vessels.

North America to Emerge as a Lucrative Region in Market

North America is expected to take the lead in the Pleural Effusion Treatment market, the reason being early adoption of advanced technology. In addition to this, a growing incidence of lung cancer and heart-related diseases in the region is calling for Pleural Effusion Treatment. Companies in this region are increasingly investing in the research and development activities to develop treatment alternatives for Pleural Effusion, thereby positively influencing regional growth.

Manufacturers to Introduce Novel Medical Devices to Improve Lives of Patients

For instance, Argon Medical Devices, a US-based company, has recently launched Single-Loop and Triple-Loop retrieval kits, which secured approval from the US Food and Drug Administration. These products eliminate any retrievable IVC filter by using a jugular approach.

Some of the key companies operating in the Pleural Effusion Treatment market include Argon Medical Devices, BD, Getinge, Uresil, Cook Medical, RTI Surgical, Denver Biomaterials, Providence Medical Technology, B. Braun, Terumo Corporation, GE Healthcare, Siemens, and Philips. Other strategies considered by the key players to stay ahead of the curve include collaborations, R&D, new product launches, and expansion.

For Acquire Full Report, Follow the link for Purchase Process: https://www.qyresearch.com/settlement/pre/6e3a6f3f2e41651829954d1d1059ca16,0,1,Global-Pleural-Effusion-Treatment-Market-Size-Status-and-Forecast

Custom Report Request @ https://www.qyresearch.com/customize-request/form/1517021/global-pleural-effusion-treatment-market

Media Contact:

Rahul Singh - Digital Marketing Director

Contact: +91 7028 920 828

Email: rahul@qyresearch.com

Sales Contact US:

USA Registered Office: QY Research, INC.

17890 Castleton, Suite 218,

City of Industry, CA - 91748

USA: +1 626 428 8800

Emails - enquiry@qyresearch.com

Web - www.qyresearch.com

https://www.qyrconsulting.com/

SOURCE: QY Research Inc.



View source version on accesswire.com:
https://www.accesswire.com/576640/QY-Research-Predicts--Global-Pleural-Effusion-Treatment-Market-to-Touch-Slightly-Over-US-65-Bn-by-2026-End

© 2020 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.